{
  "docId": "019de076-7746-74ba-85f9-63c229edc49f",
  "docSlug": "987f138dade45ff64effcbdaa91cb6f6",
  "documentTitle": "Absci | Investor Presentation Deck | 42 slides",
  "authorId": "absci",
  "authorName": "Absci",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 42,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "context",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a Kaplan-Meier survival curve as evidence for the clinical relevance of TLS.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7746-74ba-85f9-63c229edc49f/33",
  "deckHref": "/decks/019de076-7746-74ba-85f9-63c229edc49f",
  "deckJsonHref": "/decks/019de076-7746-74ba-85f9-63c229edc49f.json",
  "deckAnchorHref": "/decks/019de076-7746-74ba-85f9-63c229edc49f#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "callout",
      "text": "The presence of TLS is associated with longer progression-free survival and better response to immune checkpoint inhibitors [2,3].",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a4521eb-91d6-4829-9c8e-6654b5a939b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Kaplan-Meier curve showing progression-free survival for High vs Low Ig Staining.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebd1397a-990c-4448-baa9-6e95e4284ab9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Diagram of a TLS within a tumor showing B cells, T cells, plasma cells, and macrophages.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de4c0164-3dc5-4a0a-95b2-e0308c3f5dab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "list",
      "text": "Rapidly growing evidence illustrates correlation between TLS-derived antibodies in the tumor microenvironment and positive clinical outcomes [2]. TLS-derived antibodies have been shown to be associated with apoptosis of cancer cells in patients [2].",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77c20e4b-100c-459d-96a1-77995871b996",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "TLS are centers of immune activity (B-cell proliferation and antibody production) that develop in chronically inflamed tissues [1]. Antibodies from TLS are specialized for local antigens and play a significant role in the progression of chronic diseases and cancer, setting them apart from the general population of antibodies in the peripheral blood [2].",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39affc2d-0f8d-44e5-a467-1b8d814ed084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "[1] Pipi et al. (2018) [2] Meylan et al. (2022) [3] Helmink et al. (2020)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2890c3a-12d9-4cfe-816f-237253588384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Tertiary lymphoid structures (TLS): the cornerstone of Absci's Reverse Immunology approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90b9e6c5-e823-4beb-ab7d-1b52cd110553",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "c27a603b-b55c-4be7-b2a3-b59084c0323e",
      "evidence": "Combines biological mechanism illustration with clinical survival data to support a thesis.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}